(Press-News.org) ROCHESTER, Minn. -- Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. The study is published in the journal Cancer Discovery.
"Our findings are important because we identified genetic factors that could eventually be used to select women who should be offered the drugs for prevention," said James Ingle, M.D., an oncologist at Mayo Clinic.
Dr. Ingle and collaborators at the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the RIKEN Center for Genomic Medicine conducted a genome-wide association study involving 592 patients who developed breast cancer while receiving preventive therapy and 1,171 matched controls. Participants were selected from 33,000 women enrolled in the NSABP breast cancer prevention trials. This research was supported by a Pharmacogenomics Research Network grant from the National Institute of General Medical Science and the National Cancer Institute.
The researchers analyzed participants' DNA to identify variations in their genetic makeup and identified two genetic variations, or single nucleotide polymorphisms (SNPs), that were associated with breast cancer risk in or near the genes ZNF423 and CTSO.
They discovered that women with favorable variations in these genes were more likely to respond to preventive therapy with the drugs while women with unfavorable variations may not. In addition, women with unfavorable variations had a five-fold increased risk of developing breast cancer.
Dr. Ingle says the recent guidelines by the U.S. Preventive Services Task Force emphasize that selective estrogen receptor modulators (SERM) therapy with tamoxifen and raloxifene can lower a woman's risk for developing breast cancer. However, there currently is no way to know which women will benefit from the therapy.
"This is a major step toward truly individualized prevention of breast cancer," says Dr. Ingle. "Our findings provide clear direction as to which women are likely and which are unlikely to benefit from tamoxifen or raloxifene." Dr. Ingle says the findings provide the basis for a reinvigoration of research efforts in breast cancer prevention.
The researchers also studied breast cancer cell lines with the most common variation and the less common variation of the SNPs. They found that in cells with the most common variation of the SNPs, estrogen increased expression of both ZNF423 and CTSO and the expression of BRCA1, a gene associated with breast cancer risk. Estrogen did not increase expression of these genes in cells that had the less common form of the SNPs. Importantly, however, when tamoxifen or raloxifene were added to estrogen, there was a striking reversal in the patterns of expression of ZNF423 and BRCA1. In cells with the less common ZNF423 SNP, expression of ZNF423 and BRCA1 rose dramatically. This reversal in expression patterns provides a potential explanation for the decreased occurrence of breast cancer in women undergoing SERM therapy who carry this SNP.
###
About Mayo Clinic Cancer Center
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call
507-538-7623.
About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit http://www.mayoclinic.org/about and http://www.mayoclinic.org/news.
Journalists can become a member of the Mayo Clinic News Network for the latest health, science and research news and access to video, audio, text and graphic elements that can be downloaded or embedded.
Joe Dangor
507-284-2511 (evenings) END
Genetic variations may help identify best candidates for preventive breast cancer drugs
2013-06-13
ELSE PRESS RELEASES FROM THIS DATE:
Protein protects against breast cancer recurrence in animal model
2013-06-13
PHILADELPHIA - According to the American Cancer Society, nearly 40,000 women in the United States will succumb to breast cancer this year. Most of these women will die not from the primary tumor but rather tumor recurrence – the reappearance of the disease following treatment.
Precisely what causes breast cancer recurrence has been poorly understood. But now a piece of the puzzle has fallen into place: Researchers at the Perelman School of Medicine, University of Pennsylvania have identified a key molecular player in recurrent breast cancer – a finding that suggests ...
GW researcher finds association between finasteride and decreased levels of alcohol consumption
2013-06-13
WASHINGTON (June 11, 2013) —Researcher Michael S. Irwig, M.D., F.A.C.E., assistant professor of medicine at the George Washington University (GW) School of Medicine and Health Sciences (SMHS) and director of the Center for Andrology at The GW Medical Faculty Associates, found that men who used the medication finasteride (Propecia) and developed persistent sexual side effects, are also drinking less alcohol than before.
This research will be published in the journal, Alcoholism: Clinical & Experimental Research. While robust literature exists on the interaction between ...
Austerity cuts to Spanish healthcare system are 'putting lives at risk'
2013-06-13
A series of austerity reforms made by the Spanish government could lead to the effective dismantling of large parts of the country's healthcare system, with potentially detrimental effects on the health of the Spanish people, according to new research published in BMJ.
National budget cuts of 13.65% (€365m) and regional budget cuts of up to 10% to health and social care services in 2012 have coincided with increased demands on the health system, particularly affecting the elderly, disabled and those with poor mental health. The authors, led by the London School of Hygiene ...
Volunteering reduces risk of hypertension in older adults, Carnegie Mellon research shows
2013-06-13
PITTSBURGH—It turns out that helping others can also help you protect yourself from high blood pressure.
New research from Carnegie Mellon University shows that older adults who volunteer for at least 200 hours per year decrease their risk of hypertension, or high blood pressure, by 40 percent. The study, published by the American Psychological Association's Psychology and Aging journal, suggests that volunteer work may be an effective non-pharmaceutical option to help prevent the condition. Hypertension affects an estimated 65 million Americans and is a major contributor ...
Gene variants may predict who will benefit from breast cancer prevention drugs
2013-06-13
In women at high risk for breast cancer, a long-term drug treatment can cut the risk of developing the disease in half. Researchers supported by the National Institutes of Health have now identified two gene variants that may predict which women are most likely to benefit from this therapy—and which should avoid it.
The work represents a major step toward truly individualized breast cancer prevention in women at high risk for the disease based on their age, family history of breast cancer, and personal medical history.
"Our study reveals the first known genetic factors ...
Oysters could rebound more quickly with limited fishing and improved habitat
2013-06-13
SOLOMONS, MD (June 13, 2013)—A new study shows that combining improved oyster restoration methods with limits on fishing in the upper Chesapeake could bring the oyster population back to the Bay in a much shorter period of time. The study led by Michael Wilberg of the University of Maryland Center for Environmental Science's Chesapeake Biological Laboratory assessed a range of management and restoration options to see which ones would have the most likelihood success.
"This new model we developed suggests that oysters should be able to come back if we help them out ...
First major study of suicide motivations to advance prevention
2013-06-13
A University of British Columbia study sheds important new light on why people attempt suicide and provides the first scientifically tested measure for evaluating the motivations for suicide.
Published in the official journal of the American Association of Suicidology, the work gives doctors and researchers important new resources to advance suicide prevention, improve treatments, and reduce the likelihood of further attempts.
"Knowing why someone attempted suicide is crucial – it tells us how to best help them recover," says Prof. David Klonsky, UBC Dept. of Psychology. ...
World population could be nearly 11 billion by 2100, UW research shows
2013-06-13
A new statistical analysis shows the world population could reach nearly 11 billion by the end of the century, according to a United Nations report issued June 13. That's about 800 million, or about 8 percent, more than the previous projection of 10.1 billion, issued in 2011.
The projected rise is mostly due to fertility in Africa, where the U.N. had expected birth rates to decline more quickly than they have.
"The fertility decline in Africa has slowed down or stalled to a larger extent than we previously predicted, and as a result the African population will go ...
50 percent of rheumatoid arthritis patients discontinue medication within the first 2 years
2013-06-13
Madrid, Spain, 13 June 2013: Data presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, show that up to one-third of rheumatoid arthritis (RA) patients discontinue or change therapy within the first year of treatment.
Loss of efficacy was the most common reason given (35.8%), followed by safety (20.1%), physician or patient preference (27.8% and 17.9%, respectively) and access to treatment (9.0%). Rates and rationale for treatment discontinuation were similar for both tumour necrosis factor inhibitors (TNFi) and non-TNFi biologics.
RA ...
Childbirth increases risk of ACPA-negative rheumatoid arthritis
2013-06-13
Madrid, Spain, 13 June 2013: Epidemiological data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate that pregnancy carried to childbirth (parity) increases the risk of ACPA-negative* rheumatoid arthritis (RA).
The increased risk was demonstrated in women aged 18-44 who have had a child (2.1, 95% CI 1.4-3.2), but not in older women, and was more pronounced among those women with delivery during the first year of symptoms.
RA is an autoimmune disease characterised by inflammation of the joints and tendons. As a ...